BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.73−0.03 (-4.27%)
Close on Nov 18, 2026Market cap $2.15MP/E –Yield –
BioNexus Gene Lab free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
BioNexus Gene Lab's free cash flow for the twelve months ending Jun 30, 2026 was -$853.60K. For fiscal 2025 it was -$1.88M. The highest annual figure on record is $551.82K in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.88M | – |
| FY2024 | Dec 31, 2024 | -$2.32M | – |
| FY2023 | Dec 31, 2023 | -$1.97M | -457.3% |
| FY2022 | Dec 31, 2022 | $551.82K | +9098.6% |
| FY2021 | Dec 31, 2021 | $6.00K | -95.4% |
| FY2020 | Dec 31, 2020 | $131.06K | – |
| FY2019 | Dec 31, 2019 | -$230.09K | – |
| FY2018 | Dec 31, 2018 | -$234.46K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$422.74K | – |
| Q1 FY2026 | Mar 31, 2026 | -$148.00K | – |
| Q4 FY2025 | Dec 31, 2025 | $960.09K | +346.2% |
| Q3 FY2025 | Sep 30, 2025 | -$1.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -$759.37K | – |
| Q1 FY2025 | Mar 31, 2025 | -$833.12K | – |
| Q4 FY2024 | Dec 31, 2024 | $215.18K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.80M | – |
| Q2 FY2024 | Jun 30, 2024 | -$674.11K | – |
| Q1 FY2024 | Mar 31, 2024 | -$59.10K | – |
| Q4 FY2023 | Dec 31, 2023 | -$783.46K | -252.5% |
| Q3 FY2023 | Sep 30, 2023 | -$1.03M | -438.5% |
| Q2 FY2023 | Jun 30, 2023 | -$38.18K | – |
| Q1 FY2023 | Mar 31, 2023 | -$116.62K | – |
| Q4 FY2022 | Dec 31, 2022 | $513.88K | +6.7% |
| Q3 FY2022 | Sep 30, 2022 | $305.23K | -3.2% |
| Q2 FY2022 | Jun 30, 2022 | -$197.26K | – |
| Q1 FY2022 | Mar 31, 2022 | -$70.03K | -161.1% |
| Q4 FY2021 | Dec 31, 2021 | $481.73K | -5.8% |
| Q3 FY2021 | Sep 30, 2021 | $315.46K | -58.2% |
| Q2 FY2021 | Jun 30, 2021 | -$905.81K | – |
| Q1 FY2021 | Mar 31, 2021 | $114.62K | – |
| Q4 FY2020 | Dec 31, 2020 | $511.17K | – |
| Q3 FY2020 | Sep 30, 2020 | $754.74K | – |
| Q2 FY2020 | Jun 30, 2020 | -$157.20K | – |
| Q1 FY2020 | Mar 31, 2020 | -$977.66K | – |
| Q4 FY2019 | Dec 31, 2019 | -$65.51K | -125.1% |
| Q3 FY2019 | Sep 30, 2019 | -$53.88K | -124.1% |
| Q2 FY2019 | Jun 30, 2019 | -$76.77K | – |
| Q1 FY2019 | Mar 31, 2019 | -$33.93K | – |
| Q4 FY2018 | Dec 31, 2018 | $261.08K | – |
| Q3 FY2018 | Sep 30, 2018 | $223.33K | – |
See a number that looks wrong?